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What is Already Known about this Subject {#bcp13205-sec-0005}
========================================

Acid‐suppression medications are increasingly being prescribed in both the community and hospital settings in the UK.Omeprazole was the most commonly prescribed acid‐suppression medication by volume in Scotland in the past 2 years.Acid‐suppressing drugs have been implicated as a risk factor for bacterial gastroenteritis but meta‐analyses have provided inconsistent findings.

What this Study Adds {#bcp13205-sec-0006}
====================

In a population‐based study with good ascertainment of exposure and outcome, acid‐suppression medications were associated with increased rates of culture‐positive stool tests for presumed diarrhoea submitted from both the community and hospitals.The risk of positively testing stool samples for C. difficile and *Campylobacter* was increased with exposure to acid‐suppressing medications.Whilst acid‐suppression therapy is often considered relatively free from adverse effects, patients who are taking acid‐suppression medications need to be aware of the increased risks of bacterial gastroenteritis.

Introduction {#bcp13205-sec-0007}
============

Bacterial gastroenteritis continues to be a major global challenge with increased morbidity, mortality, and significant public health and social implications. *Clostridium difficile* is more common in the hospital setting than in the community [1](#bcp13205-bib-0001){ref-type="ref"} although community‐acquired C. difficile infection is increasing [2](#bcp13205-bib-0002){ref-type="ref"}. *C difficile* is one of the most prevalent organisms causing healthcare associated infections in Scotland, with 3634 cases in patients aged 65 years and over in 2009 with an annual overall rate for 2009 of 0.71 per 1000 total occupied bed days [3](#bcp13205-bib-0003){ref-type="ref"}. *Campylobacter, Salmonella, Shigella* and Escherichia coli O157 account for the majority of cases of bacterial pathogens identified in the community setting in Scotland, with more than 7500 reports in 2009 and the overall rate of reported *Campylobacter* infection in 2009 was 123.4 per 100 000 [4](#bcp13205-bib-0004){ref-type="ref"}. Widely documented risk factors for *Campylobacter, Salmonella, Shigella* and E. coli O157 include consumption of undercooked meat, contact with animals and foreign travel. For C. difficile, common predisposing factors include old age, antibiotic use, hospitalization, underlying comorbid illnesses and gastrointestinal procedures. There are two classes of acid‐suppression medication: proton‐pump inhibitors (PPIs), which stop acid secretion by inhibiting proton pumps located in the canalicular membrane of the parietal cell; and histamine‐2 receptor antagonists (H2RAs), which target histamine, one of the primary regulators of acid secretion. More recently, acid‐suppression medications have been implicated as a risk factor for bacterial gastroenteritis [5](#bcp13205-bib-0005){ref-type="ref"}, [6](#bcp13205-bib-0006){ref-type="ref"}, [7](#bcp13205-bib-0007){ref-type="ref"}, [8](#bcp13205-bib-0008){ref-type="ref"}, [9](#bcp13205-bib-0009){ref-type="ref"}, [10](#bcp13205-bib-0010){ref-type="ref"}, [11](#bcp13205-bib-0011){ref-type="ref"}, [12](#bcp13205-bib-0012){ref-type="ref"}, [13](#bcp13205-bib-0013){ref-type="ref"}, [14](#bcp13205-bib-0014){ref-type="ref"}, [15](#bcp13205-bib-0015){ref-type="ref"}, [16](#bcp13205-bib-0016){ref-type="ref"}, [17](#bcp13205-bib-0017){ref-type="ref"}, [18](#bcp13205-bib-0018){ref-type="ref"}. However, other studies have found no association between these bacterial infections and use of PPIs [19](#bcp13205-bib-0019){ref-type="ref"}, [20](#bcp13205-bib-0020){ref-type="ref"}, [21](#bcp13205-bib-0021){ref-type="ref"}, [22](#bcp13205-bib-0022){ref-type="ref"}, [23](#bcp13205-bib-0023){ref-type="ref"}. Acid suppression medications, such as PPIs, are increasingly being prescribed in both the community and hospital settings. The aim of this study was to investigate whether acid‐suppression medicines increase the risk of bacterial gastroenteritis.

Methods {#bcp13205-sec-0008}
=======

Study design {#bcp13205-sec-0009}
------------

This was a cohort study in which patients exposed to acid‐suppression drugs were compared to a matched cohort of patients not exposed to these drugs during the study period of January 1999 to February 2013. The cohorts were drawn from the Tayside Medicines Monitoring Unit (MEMO) database, which covers a geographically compact population and serves about 400 000 patients, mixed urban and rural, in the National Health Service in Scotland, 97% of whom are Caucasian [24](#bcp13205-bib-0024){ref-type="ref"}. The National Health Service is tax‐funded, free at the point of consumption, and covers the entire population. In Tayside, there is almost no health care delivered without the National Health Service and there is a low rate of patient migration (\<3% of patients aged ≥60 years left the Tayside region over a 5‐year period from 2004 to 2008). This population‐based, record‐linkage database contains several datasets including all dispensed community prescriptions, hospital discharge data, demographic data, laboratory results including blood, urine and stool tests, and other data, all of which are linked by a community health index number that is unique to each patient.

Study population {#bcp13205-sec-0010}
----------------

The study population consisted of residents of Tayside registered with a general practitioner (GP) between January 1999 and February 2013. It was a dynamic population that included people who registered with a GP, died or left Tayside during the study period. Patients with inflammatory bowel disease (IBD), defined as those hospitalized for or on medication for IBD, bowel cancer or gastrointestinal surgery, were excluded. Patients with \<30 days' follow‐up were also excluded from the study.

Exposed cohort {#bcp13205-sec-0011}
--------------

The exposed cohort consisted of patients who received at least one dispensed prescription of acid‐suppression drugs,either PPIs or H2RAs, during the study period. An index date was defined for each patient as the date of first exposure, or 1^st^ January 1999 if the exposure period spanned this date.

Control cohort {#bcp13205-sec-0012}
--------------

A pool of potential control patients was created by assigning index dates at random to unexposed patients by incidence density sampling from the distribution of index dates in the exposed cohort. Exposed patients could also be included as potential controls, with their follow‐up time censored at the first prescription for an acid‐suppressing drug. A control cohort was created by matching unexposed patients to each exposed patient within deciles of a propensity score distribution, and selecting two patients randomly. The propensity scores were the probabilities of exposure to acid‐suppressing drugs estimated from a logistic regression model with the covariates evaluated on each patient\'s index date. The details of covariates are listed in the next section.

Outcomes and covariates {#bcp13205-sec-0013}
-----------------------

The primary outcome was bacterial gastroenteritis defined as the composite of a stool test that was positive for C. difficile *, Campylobacter*, *Salmonella*, *Shigella* or E. coli O157 (culture‐positive tests). The secondary outcomes were individual components of the composite of the primary outcome, culture negative tests, and any completed stool test (a surrogate for symptoms of diarrhoea). A stool sample originating from primary care was classified as a community sample and one originating from a hospital in‐patient source was classified as a hospital sample.

Covariates included sex and the following, evaluated on each patient\'s index date: socioeconomic status measured by the Scottish Index of Multiple Deprivation [25](#bcp13205-bib-0025){ref-type="ref"}, history of cardiovascular disease, diabetes mellitus, pulmonary disease, renal disease, liver disease, cancer (excluding bowel cancer) and human immunodeficiency virus/acquired immune deficiency syndrome. Time dependant covariates were: age, calendar year, season (quarters), hospitalization for any reason, hospitalization with peptic ulcer, hospitalization with another infection, recent discharge (in the last 28 days) and community antibiotic use.

Definition of acid‐suppression therapy exposure {#bcp13205-sec-0014}
-----------------------------------------------

Exposure periods for PPIs and H2RAs were calculated separately. The proportions of acid‐suppression exposure were 59% for PPI and 41% for H2RAs. The quantity of drug supplied and the dosing instructions were used to estimate the length of exposure provided by each prescription. If an exposure period was followed by another prescription within 180 days it was treated as an unbroken period of exposure (a conventional and commonly used cut‐off point in drug safety research), otherwise treatment was deemed to have discontinued (Figure [1](#bcp13205-fig-0001){ref-type="fig"}). A mean daily dose was calculated over each exposure period (the sum of the daily doses on each prescribed day divided by the total length of the exposure period). PPI doses were normalized to esomeprazole by multiplying by: 1 for pantoprazole and omeprazole; 4/3 for lansoprazole, and 2 for rabeprazole. H2RA doses were standardized to cimetidine by multiplying by 8/3 for nizatidine and ranitidine and by 20 for famotidine [26](#bcp13205-bib-0026){ref-type="ref"}, [27](#bcp13205-bib-0027){ref-type="ref"}. Tertiles of each normalized dose distribution (18 and 25 mg day^--1^ for PPI, 747 and 1190 mg day^--1^ for H2RA) were used to define categorical low, medium and high dose variables for each drug class.

![Illustration of the exposure time](BCP-83-1298-g001){#bcp13205-fig-0001}

Statistical analysis {#bcp13205-sec-0015}
--------------------

Proportional hazard models, stratified by GP practice, were fitted to the time from each patient\'s index date to an outcome. The proportional hazard model assumption was checked before the analysis. Time‐dependent variables listed in the covariates section were built into the models. The primary analysis compared the exposed subjects while they continued acid‐suppression therapy with their unexposed controls over the same length of time from their respective index dates. A further set of analyses included the exposed patients only, and were designed to assess dose responses. Population attributable risks were calculated by study year for hospital and community settings. All analyses were carried out using SAS version 9.3.

Sensitivity analyses {#bcp13205-sec-0016}
--------------------

Losec, a registered trademark name of omeprazole was made available over‐the‐counter (OTC) in low dose for limited duration in 2004 and H2 antagonists were also made available OTC in low dose for limited duration in 1994. We had no record of such use. However, patients aged 60 years or older were not charged for prescribed drugs and were unlikely to purchase them OTC. To minimize any bias due to unrecorded exposure to omeprazole we did two sensitivity analyses, one with follow‐up time censored at the beginning of 2004, and another restricted to patients aged 60 years or more.

The primary analysis revealed a very large excess risk associated with hospitalization, which may have masked other effects. Therefore, in unplanned sensitivity analyses we censored each patient at their first admission to hospital following their index date. Further sensitivity analyses excluded: (i) prevalent users; (ii) patients with only one prescription of acid‐suppression drugs; and (iii) the first 15 or 30 days after index date.

We also examined heterogeneity in the effects of drug exposure between practices, and conducted a meta‐analysis to obtain a pooled estimate allowing for between‐practice variations.

Ethical approval {#bcp13205-sec-0017}
----------------

Ethical committee approval was obtained from the Tayside Committee on Medical Research Ethics. MEMO is part of Farr Institute @ Scotland.

Results {#bcp13205-sec-0018}
=======

Study population {#bcp13205-sec-0019}
----------------

We found 571 239 distinct patients registered with Tayside practices between 1999 and 2013. We excluded 2280 patients with \<30 days follow‐up in the study period, and 16 806 patients with IBD or bowel cancer. Among the remaining 552 153 eligible patients 149 636 stool tests were conducted in a total of 5.7 million patient years follow up. There were 22 705 positive test results (15 273 *C. difficile* \[toxin positive\], 6590 *Campylobacter*, 852 *Salmonella*, 129 *Shigella* and 193 E. coli O157, not mutually exclusive).

The exposed cohort consisted of 188 323 patients exposed to acid‐suppression drugs during the study period. We identified 376 646 control patients, two for each exposed patient selected randomly from unexposed patients in the same practice and the same decile of the propensity score distribution. The baseline covariates for each cohort are summarized in Table [1](#bcp13205-tbl-0001){ref-type="table-wrap"}.

###### 

Distribution of baseline covariates in the exposed cohort and a control cohort matched on a propensity score for exposure

                                                               Exposed cohort   Control cohort             
  ----------------------------------- ------------------------ ---------------- ---------------- --------- -------
  **Total patients**                                           188 323          100.0            376 646   100.0
  **Sex**                             Female                   103 468          54.9             207 520   55.1
  Male                                84 855                   45.1             169 126          44.9      
  **Age, years**                      \<10                     1707             0.9              15 884    4.2
  10--19                              8787                     4.7              18 705           5.0       
  20--29                              18 824                   10.0             30 667           8.1       
  30--39                              23 849                   12.7             43 905           11.7      
  40--49                              29 431                   15.6             57 551           15.3      
  50--59                              31 377                   16.7             62 314           16.5      
  60--69                              32 683                   17.4             64 970           17.2      
  70--79                              26 490                   14.1             52 514           13.9      
  80--89                              12 800                   6.8              25 926           6.9       
  ≥90                                 2375                     1.3              4210             1.1       
  **Socioeconomic status**            Unknown                  916              0.5              2591      0.7
  1 (most deprived)                   57 231                   30.4             115 362          30.6      
  2                                   36 554                   19.4             72 602           19.3      
  3                                   32 538                   17.3             64 737           17.2      
  4                                   41 936                   22.3             83 610           22.2      
  5 (most affluent)                   19 148                   10.2             37 744           10.0      
  **Year of index date**              1999                     39 611           21.0             93 733    24.9
  2000                                13 970                   7.4              28 302           7.5       
  2001                                12 496                   6.6              24 925           6.6       
  2002                                10 285                   5.5              20 247           5.4       
  2003                                10 522                   5.6              20 192           5.4       
  2004                                10 918                   5.8              20 024           5.3       
  2005                                11 150                   5.9              20 673           5.5       
  2006                                11 465                   6.1              20 993           5.6       
  2007                                10 365                   5.5              19 440           5.2       
  2008                                10 494                   5.6              19 507           5.2       
  2009                                10 318                   5.5              19 192           5.1       
  2010                                10 576                   5.6              20 020           5.3       
  2011                                11 557                   6.1              21 785           5.8       
  2012                                12 598                   6.7              23 947           6.4       
  2013                                1998                     1.1              3666             1.0       
  **Disease history on index date**   Cardiovascular disease   110 101          58.5             222 892   59.2
  Diabetes mellitus                   10 165                   5.4              19 075           5.1       
  Pulmonary disease                   4316                     2.3              8019             2.1       
  Renal disease                       1606                     0.9              2610             0.7       
  Liver disease                       927                      0.5              1447             0.4       
  Cancer                              6773                     3.6              12 429           3.3       
  HIV/AIDS                            76                       0.0              119              0.0       

HIV/AIDS, human immunodeficiency virus/acquired immune deficiency syndrome

Primary analysis {#bcp13205-sec-0020}
----------------

The hazard ratios (HRs) obtained from the primary analysis (i.e. for culture‐positive diarrhoea in patients exposed to acid‐suppressing drugs *vs.* an unexposed cohort) are shown in Figure [2](#bcp13205-fig-0002){ref-type="fig"}. The HR for the exposed *vs.* unexposed cohort was 2.72 (95% confidence interval \[CI\] 2.33, 3.17) for samples submitted from the community. However, there was a smaller risk associated with exposure to community prescribed acid‐suppressing drugs for samples originating in hospitals (HR = 1.28 \[95% CI 1.08, 1.52\]). Hospital in‐patients had a very high risk of culture‐positive diarrhoea when compared to out‐patients (HR = 89.7 \[95% CI 72.3, 111.2\]). If the reason for hospitalization was associated with infection the risks were even greater (HR = 11.6 \[95% CI 9.91, 13.4\]) relative to hospitalization for other reasons.

![Adjusted hazard ratios for culture‐positive stool tests in patients registered with Tayside practices, 1999 to 2013](BCP-83-1298-g002){#bcp13205-fig-0002}

The risk was also elevated in patients with human immunodeficiency virus/acquired immune deficiency syndrome or pulmonary or renal disease at baseline. There was no clear evidence of a trend with socioeconomic status. There was an increase in the rate of detection of culture‐positive diarrhoea between 1999 and 2006, and some evidence of a small decline since 2009. Risk was higher in the summer months (April to September) than in the first quarter of the year. There was little evidence of a trend with age, although patients aged 20--29 years had higher rates than other age groups.

Secondary and sensitivity analyses {#bcp13205-sec-0021}
----------------------------------

Estimates of the HR for exposed *vs.* unexposed patients in subgroup and sensitivity analyses are summarized in Table [2](#bcp13205-tbl-0002){ref-type="table-wrap"}. The HR for samples from the community was slightly lower in older patients, as would be expected if exposure to OTC omeprazole had diluted the apparent effect of acid‐suppression therapy. However, it was also lower before OTC omeprazole became available in 2004. The lowest HR was 1.29 (95% CI 1.06, 1.57) for culture‐positive samples from hospitals for patients aged over 60 years old. The exclusion of prevalent users, the first 15 days or 30 days after the index date and patients with only one prescription had little effect on the HRs for culture‐positive samples (Table [2](#bcp13205-tbl-0002){ref-type="table-wrap"}). The highest HR was 4.53 (95% CI 1.75, 11.8) for samples from hospital for *Campylobacter.*

###### 

Hazard ratios for the secondary outcomes in patients exposed to acid‐suppressing drugs *vs* unexposed matched controls

                                            Follow‐up including hospital stays   Censored at first admission   
  ----------------------------------------- ------------------------------------ ----------------------------- -------------------
  **Culture positive diarrhoea**            2.72 (2.33, 3.17)                    1.28 (1.08,1.52)              3.23 (2.71, 3.86)
  ** Before 2004**                          1.73 (1.07, 2.79)                    1.54 (1.16, 2.05)             1.77 (1.01, 3.10)
  ** Patients aged ≥60 years**              2.00 (1.63, 2.47)                    1.29 (1.06, 1.57)             2.42 (1.83, 3.22)
  ** Incident ASM users only**              2.97 (2.53,3.50)                     1.34 (1.10,1.63)              3.44 (2.82,4.16)
  ** Patients with \>1 ASM prescription**   3.26 (2.35,4.46)                     1.20 (0.87,1.67)              2.89 (2.17,3.84)
  ** Events \>15 days after index date**    2.52 (2.14,2.96)                     1.18 (0.99,1.40)              3.17 (2.64,3.80)
  ** Events \>30 days after index date**    2.77 (2.33,3.30)                     1.24 (1.03,1.49)              3.34 (2.77,4.03)
  **Clostridium difficile**                 1.70 (1.28, 2.25)                    1.42 (1.17, 1.71)             2.00 (1.25, 3.19)
  ***Campylobacter***                       3.71 (3.04, 4.53)                    4.53 (1.75, 11.8)             3.76 (3.05, 4.64)
  **Culture negative diarrhoea**            3.30 (3.10, 3.52)                    1.33 (1.25, 1.42)             3.38 (3.15, 3.63)
  **Diarrhoea (any stool sample)**          3.26 (3.07, 3.46)                    1.32 (1.24, 1.40)             3.36 (3.14, 3.59)

Adjusted for all covariates listed in the Methods section

The HRs associated with acid‐suppression with *Campylobacter* cases were 3.71 (95% CI 3.04, 4.53) for community samples, where this organism accounted for 63% of tested positive cases, and 4.53 (95% CI 1.75, 11.8) in hospitals, where it accounted for only 6% of tested positive cases. The HRs for C. difficile cases were 1.70 (95% CI 1.28, 2.25) from the community and 1.42 (95% CI 1.17, 1.71) from hospital. C. difficile accounted for 92% of positive stool cases in hospitals and 27% of tested positive cases in the community. There were too few cases of *Salmonella*, *Shigella* and *E. coli* O157 to allow analyses of these organisms individually. The HR for tested negative cases was 3.30 (95% CI 3.10, 3.52) in the community and 1.33 (95% CI 1.25, 1.42) in hospital.

Censoring follow‐up time at first hospitalization generally yielded HRs similar to or slightly higher than those obtained in the community without censoring.

Dose response relationship {#bcp13205-sec-0022}
--------------------------

Figure [3](#bcp13205-fig-0003){ref-type="fig"} shows the association between dose and primary and secondary outcomes. There was a clear dose response relationship between acid‐suppression medication and culture negative outcomes. Compared with medium dose, the HRs for low dose and high dose were 0.90 (95% CI 0.86, 0.95) and 1.06 (95% CI 1.02, 1.11) for PPIs; and 0.95 (95% CI 0.84, 1.06) and 1.16 (95% CI 1.07, 1.27) for H2RA, respectively. These findings may support a causal relationship between acid‐suppressing medications and symptoms that lead to stool culture. However, we did not observe a dose--response relationship for stool tested positive diarrhoea due to C. difficile and *Campylobacter.*

![Adjusted hazard ratios for high and low *vs.* medium doses of acid‐suppressing drugs](BCP-83-1298-g003){#bcp13205-fig-0003}

Practice heterogeneity {#bcp13205-sec-0023}
----------------------

The hazard ratios for the effect of acid‐suppression on stool test‐positive diarrhoea rates in the community estimated for each practice separately. Time‐to‐event analyses with time dependent covariates in very large datasets are not always feasible because of the computing resources required. Although we were able to conduct overall analyses in this study, we also used the methodology of meta‐analyses to pool the HRs from individual practices for comparison. The test for heterogeneity was statistically significant (*P* = 0.004), but there were no extreme outliers and the scale of the over‐dispersion was not large. The pooled HR was 2.85 (95% CI 2.39, 3.40), assuming a random effects model. This is close to the value obtained from the primary analysis and with a similar confidence interval \[2.72 (95% CI 2.33, 3.17)\].

Attributable risk {#bcp13205-sec-0024}
-----------------

The use of acid‐suppressing drugs approximately doubled over the study period (Table [3](#bcp13205-tbl-0003){ref-type="table-wrap"}). In 1999, 5.3% of patient follow‐up time in the community and 18.6% of follow‐up time for hospitalized patients were in the exposed cohort. In 2012, the exposure rates were 11.6% in the community and 35.5% in hospitals. Our estimates of exposure rates in hospital were based on the assumption that patients continued exposure to community prescribed drugs in hospital and do not include prescriptions issued in hospital.

###### 

Population attributable risk of acid‐suppression therapy for culture‐positive stool tests, 1999 to 2013

             Study population   Periods of exposure   Attributable events                                                                                                                    
  ---------- ------------------ --------------------- --------------------- ------ ----- ------- -------- ------ ----- ------- ----- ------ ----- -------- ----- ------ ------ -- ---- ----- -------
  **1999**   411 063            169                   0.41                  1156   111   96.0    21 906   5.3    74    3.38    215   18.6   30    139.5    47    27.7   0.11      7    5.9   5.68
  **2000**   409 187            397                   0.97                  1127   246   218.3   23 912   5.8    113   4.73    219   19.4   67    305.9    71    18.0   0.17      15   6.0   13.00
  **2001**   405 186            580                   1.43                  1101   380   345.1   25 870   6.4    268   10.36   220   20.0   136   618.2    169   29.2   0.42      30   7.8   27.02
  **2002**   402 901            605                   1.50                  1086   466   429.1   24 833   6.2    211   8.50    208   19.2   128   615.4    133   22.1   0.33      28   6.0   25.78
  **2003**   401 435            615                   1.53                  1063   408   383.8   27 573   6.9    240   8.70    232   21.8   120   517.2    152   24.7   0.38      26   6.4   24.69
  **2004**   402 689            1194                  2.97                  966    578   598.3   29 574   7.3    465   15.72   234   24.2   188   803.4    294   24.6   0.73      41   7.1   42.57
  **2005**   401 777            1414                  3.52                  998    587   588.2   32 768   8.2    589   17.97   267   26.8   216   809.0    372   26.3   0.93      47   8.0   47.34
  **2006**   402 192            1633                  4.06                  1020   704   690.2   34 727   8.6    714   20.56   282   27.6   267   946.8    452   27.6   1.12      58   8.3   57.26
  **2007**   403 100            1949                  4.84                  1017   926   910.5   36 279   9.0    886   24.42   302   29.7   362   1198.7   560   28.7   1.39      79   8.6   77.86
  **2008**   404 879            1828                  4.51                  1013   712   702.9   38 183   9.4    715   18.73   310   30.6   275   887.1    452   24.7   1.12      60   8.4   59.38
  **2009**   403 593            1631                  4.04                  1023   549   536.7   39 768   9.9    705   17.73   323   31.6   191   591.3    446   27.3   1.10      42   7.6   40.84
  **2010**   402 403            1361                  3.38                  993    314   316.2   41 654   10.4   564   13.54   325   32.7   118   363.1    357   26.2   0.89      26   8.2   25.99
  **2011**   401 127            1304                  3.25                  954    265   277.8   44 362   11.1   570   12.85   333   34.9   117   351.4    360   27.6   0.90      26   9.7   26.83
  **2012**   399 099            1350                  3.38                  962    291   302.5   46 101   11.6   578   12.54   351   36.5   118   336.2    366   27.1   0.92      26   8.9   26.83
  **2013**   64 473             116                   1.80                  160    22    137.5   7586     11.8   38    5.01    57    35.6   8     140.4    24    20.7   0.37      2    8.0   10.94

Cases per 1000 patient years,

\% of cases,

contribution to observed event rate

We have estimated attributable events in the community and in hospitals in each year of the study. In 2012, for example, 578 events occurred during exposure in the community and we estimate that 578 × (2.72--1)/2.72 = 366 of these (27.1% of all cases in that year) were attributable to exposure. Had there been no exposure to acid‐suppressing drugs the expected event rate would have been 2.46 per 1000 patient years (ptpy) instead of 3.38 ptpy. The contribution of exposure to the observed population event rate was therefore 0.92 ptpy.

Discussion {#bcp13205-sec-0025}
==========

We have found that acid‐suppression medicines were associated with increased risks of bacterial gastroenteritis. Patients in the community had higher risk of diarrhoea associated with acid‐suppression medicines use than patients in hospitals. The sensitivity analysis showed that the results were unlikely to be confounded by other factors.

The supposed higher risk of C. difficile infection in PPI users is based on the increased ability of the acid‐resistant spore to convert to the vegetative form and survive in a hypo‐acid environment [28](#bcp13205-bib-0028){ref-type="ref"}. Gastric acid may not effectively kill C. difficile but could alter the growth of other commensal bowel flora. Increasing acid‐suppression has previously been associated with increased risk of C. difficile infections with PPI exposure [17](#bcp13205-bib-0017){ref-type="ref"}, [29](#bcp13205-bib-0029){ref-type="ref"} but a meta‐analysis found that the quality of evidence was poor. In a separate meta‐analysis, the same authors found that H2RA exposure was associated with C. difficile infection (pooled effect estimate: 1.44, 95% CI \[1.22--1.70\]), this effect being strongest in hospitalized patients [30](#bcp13205-bib-0030){ref-type="ref"}. This is supported by our data and other meta‐analyses [16](#bcp13205-bib-0016){ref-type="ref"}. Other authors have concluded that PPI exposure is associated with a higher risk of C. difficile than H2 antagonist exposure.

Bavishi and Dupont [31](#bcp13205-bib-0031){ref-type="ref"} reviewed the evidence for the association between PPIs and bacterial gastrointestinal infection and concluded that there was evidence to support the association. However, in general, previous studies lacked access to all laboratory tests on a population basis. It was also suggested that the role of the gut microbiome in arresting pathogen colonization and growth is important for protection against C. difficile infection [32](#bcp13205-bib-0032){ref-type="ref"}, [33](#bcp13205-bib-0033){ref-type="ref"}. Seto and colleagues [33](#bcp13205-bib-0033){ref-type="ref"} hypothesized that PPI use affected the distal gut microbiome over time and they did a study in nine healthy human subjects and five treatment‐naïve subjects with C. difficile infection. They found that PPIs resulted in decreases in observed operational taxonomic unit counts, and decreases in observed species counts which were reversible after cessation of PPI usage within 1 month. This finding may be a potential explanation for the association between prolonged PPI usage and C. difficile infection incidence [33](#bcp13205-bib-0033){ref-type="ref"}. PPI use was also linked with an increased risk of serious infections including gastroenteritis in veterans with decompensated cirrhosis [34](#bcp13205-bib-0034){ref-type="ref"}. However, among hospitalized adults with C. difficile, receipt of PPIs concurrent with C. difficile treatment was not associated with C. difficile infection recurrence [35](#bcp13205-bib-0035){ref-type="ref"}.

A recent study [36](#bcp13205-bib-0036){ref-type="ref"} of the association between PPIs and *Campylobacter* and *Salmonella* infections was conducted in the general population of Wales including over one million patients. The study applied a new analysis technique: prior event rate ratio (PERR) adjustment to control both measured and unmeasured confounders (i.e. the unadjusted event rate ratio during the study was adjusted by dividing by the PERR) [37](#bcp13205-bib-0037){ref-type="ref"}. They found that the rate of *Campylobacter* and *Salmonella* infections was already at 3.1--6.9 times that of non‐PPI patients even before PPI prescription. The adjusted HR was 6.91 (95% CI 5.16, 9.26) for the PPI group when compared with the non‐PPI group. However, the ratio of events in the PPI group compared with the non‐PPI group using the prior event rate ratio was 1.17 (95% CI 0.74, 1.61) for *Campylobacter* and 1.00 (95% CI 0.5, 1.5) for *Salmonella*. The HRs of *Campylobacter* in our study were 3.71, (95% CI 3.04, 4.53) in the community and 4.53, (95% CI 1.75, 11.8) in hospital and they were significantly higher than the PERR adjusted HR of 1.7. Comparison of our study with the Welsh study should be done with caution as there are several key differences between the studies. Firstly we used a Cox regression model with a time‐dependent variable technique to address risk changes including PPI exposure over time. This is an established method in drug safety research. However, the Welsh study applied a relatively new method to get an adjusted HR. Secondly, our study was a propensity matched cohort study with a mean follow‐up of 10 years while the Welsh study only used 2 years of data for their cohort study (i.e. the 12‐month period before PPI prescription and the 12‐month period post‐PPI prescription) and the control group was only matched for date with the PPI patients (matched on day, month, year). Thirdly, the Welsh study used prescribed prescriptions for exposure, while our study used dispensed prescriptions which would eliminate primary noncompliance as a previous study showed that some patients do not collect their prescriptions at a pharmacy [38](#bcp13205-bib-0038){ref-type="ref"}. The association between *Campylobacter* and PPI use has also been supported by a recent ecological study from The Netherlands and a study from the UK [39](#bcp13205-bib-0039){ref-type="ref"}, [40](#bcp13205-bib-0040){ref-type="ref"}. The high risk for tested negative cases in the community (HR, 3.3) and in hospital (1.33) suggests that acid‐suppressing therapy itself may lead to symptoms that result in a stool sample being submitted. In fact, these cases of culture‐negative diarrhoea are probably due to an organism that has not been detected, as culture‐positive specimens represent only a fraction of infections that actually occur in the community or hospital populations.

Although not the primary reason for carrying out the study, we also found that very high hazards of culture‐positive stool samples were associated with recent hospitalization (HR = 89.7 \[95% CI 72.3, 111.2\]) or hospitalization with an infection (HR = 11.6 \[95% CI 9.9, 13.7\]) or with community antibiotic use (HR = 2.3 \[95% CI 2.0, 2.6\]). Thus, the effects of hospitalization and antibiotic use appear to be the dominant associations with culture‐positive stool samples. Finally, acid‐suppressing therapy showed a dose‐dependent association with an increased risk of culture negative sample submission, supporting the hypothesis that these drugs themselves induce diarrhoea that leads to stool sample submission.

Our study has some strengths and limitations. We used a well validated population‐based record linkage database with complete ascertainment of all stool samples submitted to the regional laboratory. It was possible to determine the source of the stool samples, whether originating from the community or hospitals. The database contained exposure data on dispensed medications (rather than prescribed medications) thus eliminating misclassification caused by primary noncompliance and we could decode the intended dose and duration of medications. The study population had an excellent roster file that allowed complete ascertainment of subject eligibility over time and record‐linkage was deterministic (not probabilistic) resulting in more accurate linkage. We were able to track subjects\' membership of individual primary care practices, to measure a social deprivation score and to obtain good data on comorbidities.

A limitation of the MEMO database is that exposure to nonprescription drugs is not recorded, and omeprazole and H2RAs have been available OTC since 2004 albeit in lower doses. There are no culture data for viral causes of diarrhoea, and only a restricted range of bacterial pathogens was investigated in the study. Nonsteroidal anti‐inflammatory drug use was not adjusted for in the analysis, but these drugs increase intestinal permeability and may predispose to inflammation or even susceptibility to infection. Parasitic infections were also not included in the study outcome. Also, since MEMO does not have information on disease severity, smoking, body mass index, alcohol and other factors, which might be linked to diarrhoea, we were unable to use them as matching criteria. Although we used a propensity score to build an unexposed cohort using available risk factors, and we adjusted for multiple covariates and carried out sensitivity analyses, we cannot exclude effects due to unrecognized or unrecorded confounding factors. The effect of discontinuing drugs is difficult to assess because the date of discontinuation is estimated from the last known prescription and is subject to error. Short‐term effects, in particular, are likely to be underestimated. Our estimates of attributable risk take no account of any effects of discontinuation, and may therefore be underestimates.

In conclusion, acid‐suppressing therapy with PPIs or H2RAs increased the risk of both bacterial gastrointestinal infections and culture negative stool samples submitted for presumed diarrhoea. Compared with subjects not taking PPIs or H2RAs, community‐prescribed PPIs and H2RAs were associated with increased rates of positive stool samples for C. difficile and *Campylobacter* submitted from both the community and hospitals. Whilst acid‐suppression therapy is often considered relatively free from adverse effects this present study suggests that there are significant adverse gastrointestinal noninfective and infective consequences of their use.
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